XBiotech Inc. financial data

Symbol
XBIT on Nasdaq
Location
Austin, TX
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2277% % 64%
Debt-to-equity 5% % -35%
Return On Equity -17% % -4.6%
Return On Assets -16% % -7.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 30,487,731 shares 0.01%
Common Stock, Shares, Outstanding 30,487,731 shares 0.03%
Entity Public Float $121,869,724 USD -13%
Common Stock, Value, Issued $276,565,000 USD 1.5%
Weighted Average Number of Shares Outstanding, Basic 30,487,731 shares 0.05%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $29,856,000 USD -21%
General and Administrative Expense $4,825,000 USD 5.6%
Operating Income (Loss) $34,681,000 USD 18%
Nonoperating Income (Expense) $5,643,000 USD -41%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $29,038,000 USD 11%
Income Tax Expense (Benefit) $118,000 USD 1033%
Net Income (Loss) Attributable to Parent $29,156,000 USD 11%
Earnings Per Share, Basic 0 USD/shares 10%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $147,367,000 USD -20%
Accounts Receivable, after Allowance for Credit Loss, Current $450,000 USD -38%
Assets, Current $148,951,000 USD -20%
Property, Plant and Equipment, Net $23,473,000 USD -5.4%
Assets $172,424,000 USD -18%
Accounts Payable, Current $1,043,000 USD -31%
Employee-related Liabilities, Current $611,000 USD 8.7%
Accrued Liabilities, Current $2,422,000 USD -46%
Liabilities, Current $3,565,000 USD -78%
Accrued Income Taxes, Noncurrent $1,779,000 USD 2%
Liabilities $5,344,000 USD -70%
Retained Earnings (Accumulated Deficit) $109,485,000 USD -36%
Stockholders' Equity Attributable to Parent $167,080,000 USD -13%
Liabilities and Equity $172,424,000 USD -18%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $6,720,000 USD 6.7%
Net Cash Provided by (Used in) Financing Activities $10,250,000 USD -202%
Net Cash Provided by (Used in) Investing Activities $94,000 USD 63%
Common Stock, Shares, Issued 30,487,731 shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $16,780,000 USD -1752%
Interest Paid, Excluding Capitalized Interest, Operating Activities $486,000 USD 22%
Deferred Tax Assets, Valuation Allowance $26,382,000 USD 50%
Deferred Tax Assets, Gross $26,777,000 USD 47%
Depreciation $442,000 USD 2.3%
Payments to Acquire Property, Plant, and Equipment $94,000 USD -63%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $38,531,000 USD -52%
Deferred Tax Assets, Operating Loss Carryforwards $2,799,000 USD 117%
Unrecognized Tax Benefits $3,434,000 USD 16%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $395,000 USD -37%
Share-based Payment Arrangement, Expense $4,088,000 USD 125%